FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

DoJ Probing Inspire Marketing, Reimbursement

The Department of Justice has requested information from Inspire Medical as part of a civil probe into its marketing, promotion, and reimbursement pra...

Human Drugs

FDA Clarifies Compounded GLP-1 Enforcement

FDA clarifies its enforcement discretion timeframes for compounded tirzepatide.

latest-news-card-1
Human Drugs

Genentech Gets New Evrysdi Tablet Approval

FDA approves a Genentech NDA for a new tablet formulation of Evrysdi (risdiplam) for treating people with spinal muscular atrophy.

latest-news-card-1
Human Drugs

Regeneron BLA Resubmitted for Multiple Myeloma

FDA accepts for review a Regeneron Pharmaceuticals BLA resubmission for linvoseltamab for treating adult patients with relapsed/refractory multiple my...

latest-news-card-1
Medical Devices

Change FDA AI Policies: Gottlieb

Former FDA commissioner Scott Gottlieb says the agency should revert to clinical decision support system regulatory policies approved during his tenur...

latest-news-card-1
Human Drugs

Strukmyer Medical CGMP Violations

FDA warns Mesquite, TX-based Strukmyer Medical about CGMP violations in manufacturing finished drugs and cosmetics.

latest-news-card-1
Human Drugs

Chengdu Records Review Finds CGMP Deviations

FDA warns Chinas Chengdu Innovation Pharmaceutical Co. about CGMP deviations in manufacturing active pharmaceutical ingredients.

latest-news-card-1

Court Orders FDA to Restore Gender Web Pages

DC federal judge John Bates orders FDA and CDC to re-post Web pages and datasets they removed to comply with President Trumps executive order on gende...

latest-news-card-1
Human Drugs

Change FDA Approach to Antibiotic Approval: Column

A STAT First Opinion column calls on FDA to focus on how effective new antibiotics are in real-world patients, rather than approving them based on how...

latest-news-card-1
Human Drugs

Biohaven NDA Filed for Spinocerebellar Ataxia Drug

FDA accepts for priority review a Biohaven NDA for troriluzole for treating adult patients with spinocerebellar ataxia.